Astellas subsidiary to partner with Pittsburgh upstart in search for 'undruggable' proteins

Tyler Patchen

News Reporter

As Astellas continues its drive to build out its gene therapy portfolio and capabilities, a subsidiary of the Japanese pharma company has entered into a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas subsidiary to partner with Pittsburgh upstart in search for 'undruggable' proteins

Tyler Patchen

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Astel­las sub­sidiary to part­ner with Pitts­burgh up­start in search for 'un­drug­gable' pro­teins

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Astellas subsidiary to partner with Pittsburgh upstart in search for 'undruggable' proteins